Patient motivation and adherence to an on-demand app-based heart rate and rhythm monitoring for atrial fibrillation management: data from the TeleCheck-AF project.

The aim of this TeleCheck-AF sub-analysis was to evaluate motivation and adherence to on-demand heart rate/rhythm monitoring app in patients with atrial fibrillation (AF). Patients were instructed to perform 60 s app-based heart rate/rhythm recordings 3 times daily and in case of symptoms for 7 consecutive days prior to teleconsultation. Motivation was defined as number of days in which the expected number of measurements (≥3/day) were performed per number of days over the entire prescription period. Adherence was defined as number of performed measurements per number of expected measurements over the entire prescription period.Data from 990 consecutive patients with diagnosed AF [median age 64 (57-71) years, 39% female] from 10 centres were analyzed. Patients with both optimal motivation (100%) and adherence (≥100%) constituted 28% of the study population and had a lower percentage of recordings in sinus rhythm [90 (53-100%) vs. 100 (64-100%), P < 0.001] compared with others. Older age and absence of diabetes were predictors of both optimal motivation and adherence [odds ratio (OR) 1.02, 95% coincidence interval (95% CI): 1.01-1.04, P < 0.001 and OR: 0.49, 95% CI: 0.28-0.86, P = 0.013, respectively]. Patients with 100% motivation also had ≥100% adherence. Independent predictors for optimal adherence alone were older age (OR: 1.02, 95% CI: 1.00-1.04, P = 0.014), female sex (OR: 1.70, 95% CI: 1.29-2.23, P < 0.001), previous AF ablation (OR: 1.35, 95% CI: 1.03-1.07, P = 0.028). In the TeleCheck-AF project, more than one-fourth of patients had optimal motivation and adherence to app-based heart rate/rhythm monitoring. Older age and absence of diabetes were predictors of optimal motivation/adherence.

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Déclaration de conflit d'intérêts

Conflict of interests: M.G., A.N.L.H., R.M.J.v.d.V., K.B., D.V.M.V., H.A.K.Hi., D.Sc., J.M., A.Su., D.St., E.T., R.P., M.H., L.V., P.L., B.K., L.P., H.G., L.D., H.He., T.d.P., N.A.H.A.P., A.So., D.L., J.M.H. declared no conflicts of interest. D.G. received PI for institutional research grants from Biosense Webster, Boston Scientific, and Medtronic. N.K. has received research grants from the Swiss National Science Foundation (P400PM-194477), Gottfried und Julia Bangerter-Rhyner-Stiftung, and the European Society of Cardiology. S.E. was employed by Qompium NV. K.V. is a consultant for Medronic, Abbott, Biosense Webster, Philips. M.M. has received speaker honoraria and/or travel grants from Biosense Webster, Abbott, Biotronik, Zoll, Boston Scientific, Daiichi Sankyo, Bayer, Pfizer, Amomed, as well as research grants from Biosense Webster. D.D. received lecture honorary, travel grants and/or a fellowship grant from Abbott, Astra Zeneca, Bayer, Biotronik, Bristol-Myers Squibb, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Medtronic, Microport, Pfizer, Zoll. E.S. has received institutional lecture/consulting fees from lecture fees from Bayer, Bristol-Myers Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme, and Sanofi.